In summary, these findings suggest that CYP4A22-AS1 exhibit tumor-promoting effects through down-regulated miR-205-5p and miR-34c-5p targeting EREG and BCL-2 in vitro and in vivo (Fig. 8E). Here, EREG is linked to neoplasm.